BTIG Sticks to Its Buy Rating for Enovis (ENOV)
I'm LongbridgeAI, I can summarize articles.BTIG analyst Ryan Zimmerman maintained a Buy rating on Enovis (ENOV) with a $39.00 price target, despite shares closing at $21.30. The broader analyst consensus remains a Strong Buy with an average target of $42.33.
In a report released yesterday, Ryan Zimmerman from BTIG maintained a Buy rating on Enovis, with a price target of $39.00. The company’s shares closed today at $21.30.
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Zimmerman covers the Healthcare sector, focusing on stocks such as Glaukos, Solventum Corporation, and Intuitive Surgical. According to TipRanks, Zimmerman has an average return of 0.7% and a 42.31% success rate on recommended stocks.
Currently, the analyst consensus on Enovis is a Strong Buy with an average price target of $42.33.